Psychedelics最新文献

筛选

英文中文

Single-dose psychedelic enhances cognitive flexibility and reversal learning in mice weeks after administration. 单剂量迷幻药在给药后几周增强小鼠的认知灵活性和逆向学习。

Psychedelics Pub Date : 2025-04-22 DOI: 10.61373/pp025r.0002

Elizabeth J Brouns, Tyler G Ekins, Omar J Ahmed

{"title":"Single-dose psychedelic enhances cognitive flexibility and reversal learning in mice weeks after administration.","authors":"Elizabeth J Brouns, Tyler G Ekins, Omar J Ahmed","doi":"10.61373/pp025r.0002","DOIUrl":"10.61373/pp025r.0002","url":null,"abstract":"Psychedelic compounds have demonstrated remarkable therapeutic potential for treating neuropsychiatric disorders by promoting sustained neuroplasticity in the prefrontal cortex (PFC). Cognitive flexibility-the ability to adapt previously learned rules to novel situations-represents a critical PFC function that is frequently impaired in depression, PTSD, and neurodegenerative conditions. In this study, we demonstrate that a single administration of the selective serotonin 2A receptor agonist 25CN-NBOH produces significant, long-lasting improvements in cognitive flexibility in both male and female mice when measured 2-3 weeks posttreatment. Using a novel automated sequential learning paradigm, psychedelic-treated mice showed superior adaptability in rule reversal tasks compared to saline controls, as evidenced by enhanced poke efficiency, higher percentages of correct trials, and increased reward acquisition. These behavioral findings complement existing cellular research showing psychedelic-induced structural remodeling in the PFC and uniquely demonstrate sustained cognitive benefits persisting weeks after a single psychedelic dose. Our automated behavioral task provides a high-throughput method for evaluating cognitive flexibility effects of various psychedelic compounds, offering important implications for therapeutic applications in conditions characterized by cognitive rigidity, including depression, PTSD, and potentially Alzheimer's disease.","PeriodicalId":520871,"journal":{"name":"Psychedelics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder. 单剂量裸盖菇素改变身体畸形障碍患者静息状态功能网络。

Psychedelics Pub Date : 2025-01-01 Epub Date: 2024-09-24 DOI: 10.61373/pp024r.0028

Xi Zhu, Chen Zhang, David Hellerstein, Jamie D Feusner, Michael G Wheaton, Gloria J Gomez, Franklin Schneier

{"title":"Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder.","authors":"Xi Zhu, Chen Zhang, David Hellerstein, Jamie D Feusner, Michael G Wheaton, Gloria J Gomez, Franklin Schneier","doi":"10.61373/pp024r.0028","DOIUrl":"10.61373/pp024r.0028","url":null,"abstract":"Body dysmorphic disorder (BDD) is a severe psychiatric condition characterized by preoccupation with perceived flaws in one's appearance, which the individual views as defective or ugly. Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, has emerged as a potential therapeutic agent for depression and other psychiatric disorders. This study aimed to identify subacute neural changes predicting symptomatic response to psilocybin treatment in adults with BDD. Eight adults with moderate-to-severe nondelusional BDD were administered a single oral 25 mg dose of psilocybin, accompanied by psychological support, and underwent resting state functional magnetic resonance imaging assessments 1 day before and 1 day after the dosing. Both a region of interest (ROI)-to-ROI analysis and multivariate pattern analysis (MVPA) were used to identify changes in resting state functional connectivity (rsFC) at day 1 after dosing that predicted treatment response at week 1, measured by change in Yale-Brown Obsessive Compulsive Disorder Scale Modified for BDD (BDDYBOCS) score. All participants completed the dosing and follow-up assessments over 12 weeks. BDD-YBOCS scores decreased at week 1 and week 12 after dosing (p<0.001 for both). MVPA revealed a significant increase in rsFC within the Executive Control Network (ECN) at day 1. Increased rsFC within the ECN (dlPFC - Superior Parietal Lobule [FPL]), between the ECN and Default Mode Network (dlPFC - Precuneus), and between the ECN and the Salience Network (dlPFC - insula) were predictive of improvement in BDD symptoms at week 1. These findings are the first report of subacute brain effects of psilocybin in patients with BDD. Given the small sample size and uncontrolled design of the study, larger controlled studies are necessary to validate these observations. Clinical Trials Registration: Clinicaltrials.gov ID: NCT04656301.","PeriodicalId":520871,"journal":{"name":"Psychedelics","volume":"1 1","pages":"25-31"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0